BridgeBio Pharma, Inc. Lease, Cost
BridgeBio Pharma, Inc. (BBIO) reported Lease, Cost of $2.56 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-08-10
- BridgeBio Pharma, Inc. lease, cost for the quarter ending 2026-06-30 was $2.56M, a 6.79% increase year-over-year.
- BridgeBio Pharma, Inc. lease, cost for the quarter ending 2026-03-31 was $2.27M, a 8.82% decline year-over-year.
- BridgeBio Pharma, Inc. lease, cost for the quarter ending 2025-12-31 was $2.14M, a 11.37% decline year-over-year.
- BridgeBio Pharma, Inc. lease, cost for the quarter ending 2025-09-30 was $2.65M, a 1.46% increase year-over-year.
- BridgeBio Pharma, Inc. lease, cost for fiscal 2025 was $9.69M, a 10.40% decline from fiscal 2024.
- BridgeBio Pharma, Inc. lease, cost for fiscal 2024 was $10.81M, a 4.30% decline from fiscal 2023.
- BridgeBio Pharma, Inc. lease, cost for fiscal 2023 was $11.30M, a 3.92% decline from fiscal 2022.
- BridgeBio Pharma, Inc. lease, cost for fiscal 2022 was $11.76M, a 14.64% increase from fiscal 2021.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.56M 10-Q · filed 2026-08-10 | $4.84M 10-Q · filed 2026-08-10 | $6.98M derived: sum of 3 quarters · filed 2026-08-10 | $9.63M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $2.27M 10-Q · filed 2026-05-07 | $4.42M derived: sum of 2 quarters · filed 2026-05-07 | $7.06M derived: sum of 3 quarters · filed 2026-05-07 | $9.47M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $2.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $4.79M derived: sum of 2 quarters · filed 2026-02-24 | $7.19M derived: sum of 3 quarters · filed 2026-08-10 | $9.69M 10-K · filed 2026-02-24 |
| 2025-09-30 | $2.65M 10-Q · filed 2025-10-29 | $5.05M derived: sum of 2 quarters · filed 2026-08-10 | $7.54M 10-Q · filed 2025-10-29 | $9.96M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $2.40M 10-Q · filed 2026-08-10 | $4.90M 10-Q · filed 2026-08-10 | $7.32M derived: sum of 3 quarters · filed 2026-08-10 | $9.92M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $2.50M 10-Q · filed 2026-05-07 | $4.91M derived: sum of 2 quarters · filed 2026-05-07 | $7.52M derived: sum of 3 quarters · filed 2026-05-07 | $10.12M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $2.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $5.03M derived: sum of 2 quarters · filed 2026-02-24 | $7.63M derived: sum of 3 quarters · filed 2026-02-24 | $10.81M 10-K · filed 2026-02-24 |
| 2024-09-30 | $2.61M 10-Q · filed 2025-10-29 | $5.21M derived: sum of 2 quarters · filed 2025-10-29 | $8.39M 10-Q · filed 2025-10-29 | $11.16M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $2.60M 10-Q · filed 2025-08-05 | $5.78M 10-Q · filed 2025-08-05 | $8.55M derived: sum of 3 quarters · filed 2026-02-24 | $11.43M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $3.18M 10-Q · filed 2025-04-29 | $5.95M derived: sum of 2 quarters · filed 2026-02-24 | $8.82M derived: sum of 3 quarters · filed 2026-02-24 | $11.62M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $2.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $5.64M derived: sum of 2 quarters · filed 2026-02-24 | $8.44M derived: sum of 3 quarters · filed 2026-02-24 | $11.30M 10-K · filed 2026-02-24 |
| 2023-09-30 | $2.87M 10-Q · filed 2024-11-12 | $5.67M derived: sum of 2 quarters · filed 2024-11-12 | $8.53M 10-Q · filed 2024-11-12 | $11.30M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-06-30 | $2.80M 10-Q · filed 2024-08-01 | $5.66M 10-Q · filed 2024-08-01 | $8.43M derived: sum of 3 quarters · filed 2025-02-20 | $11.23M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-03-31 | $2.86M 10-Q · filed 2024-05-02 | $5.63M derived: sum of 2 quarters · filed 2025-02-20 | $8.44M derived: sum of 3 quarters · filed 2025-02-20 | $11.40M derived: sum of 4 quarters · filed 2025-02-20 |
| 2022-12-31 | $2.77M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $5.58M derived: sum of 2 quarters · filed 2025-02-20 | $8.54M derived: sum of 3 quarters · filed 2025-02-20 | $11.76M 10-K · filed 2025-02-20 |
| 2022-09-30 | $2.81M 10-Q · filed 2023-11-02 | $5.77M derived: sum of 2 quarters · filed 2023-11-02 | $8.98M 10-Q · filed 2023-11-02 | $12.04M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $2.96M 10-Q · filed 2023-08-03 | $6.18M 10-Q · filed 2023-08-03 | $9.24M derived: sum of 3 quarters · filed 2024-02-22 | $11.92M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $3.22M 10-Q · filed 2023-05-04 | $6.28M derived: sum of 2 quarters · filed 2024-02-22 | $8.96M derived: sum of 3 quarters · filed 2024-02-22 | $11.30M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $3.06M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $5.74M derived: sum of 2 quarters · filed 2024-02-22 | $8.08M derived: sum of 3 quarters · filed 2024-02-22 | $10.26M 10-K · filed 2024-02-22 |
| 2021-09-30 | $2.68M 10-Q · filed 2022-11-03 | $5.02M derived: sum of 2 quarters · filed 2022-11-03 | $7.20M 10-Q · filed 2022-11-03 | $8.58M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $2.34M 10-Q · filed 2022-08-04 | $4.51M 10-Q · filed 2022-08-04 | $5.90M derived: sum of 3 quarters · filed 2023-02-23 | $7.15M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $2.17M 10-Q · filed 2022-05-05 | $3.56M derived: sum of 2 quarters · filed 2023-02-23 | $4.81M derived: sum of 3 quarters · filed 2023-02-23 | $5.95M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $1.39M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $2.64M derived: sum of 2 quarters · filed 2023-02-23 | $3.77M derived: sum of 3 quarters · filed 2023-02-23 | $4.63M 10-K · filed 2023-02-23 |
| 2020-09-30 | $1.25M 10-Q · filed 2021-11-04 | $2.39M derived: sum of 2 quarters · filed 2021-11-04 | $3.24M 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $1.14M 10-Q · filed 2021-08-05 | $1.99M 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | $853.00K 10-Q · filed 2021-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |